Pages that link to "Q71059798"
Jump to navigation
Jump to search
The following pages link to Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125 (Q71059798):
Displaying 50 items.
- High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma (Q24658024) (← links)
- Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma (Q24791107) (← links)
- Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer (Q28346751) (← links)
- Carcinosarcoma of the ovary: 19 years of prospective data from a single center. (Q30930233) (← links)
- Effects of blood collection conditions on ovarian cancer serum markers (Q33308744) (← links)
- Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma (Q33341835) (← links)
- Effect of topotecan infusion duration on hematologic toxicity in recurrent ovarian carcinoma (Q33342528) (← links)
- Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer (Q33346522) (← links)
- Phase II trial of Oxaliplatin and 5-Fluorouracil/Leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy (Q33362032) (← links)
- Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer (Q33362035) (← links)
- A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma (Q33364598) (← links)
- Evaluation of weekly low-dose paclitaxel and carboplatin treatment for patients with platinum-sensitive relapsed ovarian cancer (Q33364604) (← links)
- Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study. (Q33365433) (← links)
- Sequential gemcitabine-carboplatin followed by paclitaxel-carboplatin in the first-line treatment of advanced ovarian cancer: A phase II study (Q33369125) (← links)
- Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up (Q33369422) (← links)
- Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial (Q33374033) (← links)
- Weekly topotecan for recurrent platinum resistant ovarian cancer (Q33376847) (← links)
- Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer (Q33379246) (← links)
- Phase II trial of carboplatin and distearoylphosphatidylcholine pegylated liposomal doxorubicin (Lipo-Dox) in recurrent platinum-sensitive ovarian cancer following front-line therapy with paclitaxel and platinum (Q33381866) (← links)
- Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: a French multicenter phase II study (Q33386338) (← links)
- Association of pegylated liposomal doxorubicin and ifosfamide in early recurrent ovarian cancer patients: a multicenter phase II trial (Q33386936) (← links)
- Sequential chemotherapy with carboplatin followed by weekly paclitaxel in advanced ovarian cancer: results of a multicenter phase II study of the northeastern German society of gynecological oncology (Q33387307) (← links)
- Feasibility of Oxaliplatin, Leucovorin, and 5-Fluorouracil (FOLFOX-4) Chemotherapy in Heavily Pretreated Patients with Recurrent Epithelial Ovarian Cancer (Q33407256) (← links)
- Topotecan in Platinum- and Paclitaxel-Resistant Ovarian Cancer (Q33500327) (← links)
- Tumor markers: reclassification and new approaches to evaluation (Q33543590) (← links)
- Combination of irinotecan and platinum for platinum-resistant or refractory recurrent ovarian cancers: A preliminary case series (Q33858199) (← links)
- Role of tumour markers in monitoring epithelial ovarian cancer (Q33903011) (← links)
- Pharmacoeconomic considerations in treating ovarian cancer (Q33914363) (← links)
- Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary (Q34103978) (← links)
- Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma (Q34150824) (← links)
- Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer (Q35040690) (← links)
- The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma (Q35094175) (← links)
- Current state of biomarker development for clinical application in epithelial ovarian cancer (Q35100951) (← links)
- Limitations to the use of the CA-125 antigen level in ovarian cancer (Q35142811) (← links)
- Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer. (Q35160419) (← links)
- Prevalence of Epithelial Ovarian Cancer Stem Cells Correlates with Recurrence in Early-Stage Ovarian Cancer (Q35195618) (← links)
- A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: an analysis of patients enrolled in GOG 172. (Q35234443) (← links)
- Weekly paclitaxel infusion as salvage therapy in ovarian cancer (Q35589197) (← links)
- Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study (Q35633159) (← links)
- The GOFURTGO Study: AGITG phase II study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer (Q35653846) (← links)
- The value of serum CA125 for the development of virtual follow-up strategies for patients with epithelial ovarian cancer: a retrospective study (Q35916044) (← links)
- Diagnostic and prognostic evaluation of fluorodeoxyglucose positron emission tomography/computed tomography and its correlation with serum cancer antigen-125 (CA125) in a large cohort of ovarian cancer patients (Q36029023) (← links)
- Combined panel of serum human tissue kallikreins and CA-125 for the detection of epithelial ovarian cancer (Q36090095) (← links)
- Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer (Q36136230) (← links)
- Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma (Q36170289) (← links)
- Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers (Q36372283) (← links)
- Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation (Q36620469) (← links)
- A dose-finding study of carboplatin-epirubicin-docetaxel in advanced epithelial ovarian cancer (Q36644381) (← links)
- A phase II trial of capecitabine (Xeloda®) in recurrent ovarian cancer (Q36671560) (← links)
- Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma? (Q36694465) (← links)